Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma (RRMM)”

79 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 79 results

Testing effectiveness (Phase 2)WithdrawnNCT03856112
What this trial is testing

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myelomat(11;14) Negative
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05909826
What this trial is testing

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Dong-A University Hospital 49
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Testing effectiveness (Phase 2)Active Not RecruitingNCT05911321
What this trial is testing

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Who this might be right for
Multiple MyelomaRelapseRefractory+2 more
UNC Lineberger Comprehensive Cancer Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT06171685
What this trial is testing

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Multiple Myeloma Research Consortium 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Not applicableActive Not RecruitingNCT04458831
What this trial is testing

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Plasma Cell Myeloma
Sanofi 583
Testing effectiveness (Phase 2)Looking for participantsNCT07266441
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 157
Large-scale testing (Phase 3)Looking for participantsNCT06158841
What this trial is testing

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 380
Testing effectiveness (Phase 2)Study completedNCT03439293
What this trial is testing

Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Takeda 61
Large-scale testing (Phase 3)Active Not RecruitingNCT04939142
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Antengene Corporation 150
Testing effectiveness (Phase 2)Looking for participantsNCT06356571
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 64
Testing effectiveness (Phase 2)Looking for participantsNCT06645678
What this trial is testing

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH 75
Load More Results